Most importantly, he found differential expression changes that always led to prosurvival adaptation of senescent cells ...

They found that targeting the protein BCL-XL, which plays a major role in helping cancer cells avoid death, could enhance the effectiveness of treatments in certain cases. The researchers then ...

Ascentage Pharma Group International’s AAPG share price has surged by 7.56%, which has investors questioning if this is right time to sell.

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Ascentage Pharma Group International’s AAPG share price has dipped by 6.94%, which has investors questioning if this is right time to buy.

UBX1325 is UNITY Biotechnology’s novel BCL-xL inhibitor with a unique mechanism of action. The data readout from the mid-stage DME study demonstrated that treatment with the candidate resulted ...